Pharma Investment Surge in US Manufacturing Creates Major Opportunities for CDMOs

US pharmaceutical manufacturing; CDMOs; capital investment; Johnson & Johnson; Eli Lilly; biologics; API production; supply chain; advanced therapies; market growth

Eli Lilly Invests $6.5 Billion in Texas Facility to Manufacture Obesity Pill

Eli Lilly; Texas facility; obesity pill; orforglipron; pharmaceutical manufacturing; API; AI automation; supply chain resilience; job creation

FDA Issues Warning Letter to J&J Subsidiary Over Stopper Issues and Quality Reporting at Korean Plant

FDA warning letter; Johnson & Johnson subsidiary; Janssen Vaccines; Korean production plant; vial stopper defects; quality control violations; spotty complaint reporting; good manufacturing practices; Incheon; pharmaceutical manufacturing

Eli Lilly Picks Houston for $6.5 Billion API Manufacturing Facility

Eli Lilly; Houston; API manufacturing; $6.5 billion investment; Generation Park; small molecule medicines; pharmaceutical manufacturing; cardiometabolic; oncology; immunology; neuroscience

Hikal Receives US FDA Warning Letter Over Metal Contamination at Jigani Facility

Hikal; FDA warning letter; metal contamination; API manufacturer; GMP violations; Jigani facility; India; pharmaceutical manufacturing; regulatory compliance

AbbVie Invests $195 Million in New North Chicago API Manufacturing Site

AbbVie; North Chicago; API manufacturing; $195 million investment; facility expansion; pharmaceutical manufacturing; Illinois; domestic production

Sarepta Therapeutics Faces FDA Crackdown after Third Patient Death; George Tidmarsh Named Top FDA Drug Regulator; Multiple Drugs Rejected; Pharma Invests Billions in US Manufacturing

Sarepta Therapeutics; FDA; gene therapy; Elevidys; acute liver failure; clinical hold; George Tidmarsh; drug rejection; reshoring; pharmaceutical manufacturing

Thermo Fisher to Acquire Sanofi Factory; Amphastar Plans Major HQ Expansion

Thermo Fisher; Sanofi; acquisition; sterile manufacturing; Ridgefield New Jersey; fill-finish; pharmaceutical manufacturing; Amphastar; headquarters expansion; capacity quadruple; California